BR112012013503A2 - suspensões de nanopartícula contendo polímero de carboxivinila - Google Patents

suspensões de nanopartícula contendo polímero de carboxivinila

Info

Publication number
BR112012013503A2
BR112012013503A2 BR112012013503A BR112012013503A BR112012013503A2 BR 112012013503 A2 BR112012013503 A2 BR 112012013503A2 BR 112012013503 A BR112012013503 A BR 112012013503A BR 112012013503 A BR112012013503 A BR 112012013503A BR 112012013503 A2 BR112012013503 A2 BR 112012013503A2
Authority
BR
Brazil
Prior art keywords
carboxyvinyl polymer
containing nanoparticle
compound
nanoparticle suspensions
compositions
Prior art date
Application number
BR112012013503A
Other languages
English (en)
Other versions
BR112012013503B8 (pt
BR112012013503B1 (pt
Inventor
Bahram Asgharian
Malay Ghosh
Masood A Chowhan
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43425837&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012013503(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012013503A2 publication Critical patent/BR112012013503A2/pt
Publication of BR112012013503B1 publication Critical patent/BR112012013503B1/pt
Publication of BR112012013503B8 publication Critical patent/BR112012013503B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

suspensões de nanopartículas contendo polímero de carboxivinila. a presente invenção refere-se geralmente a composições de suspensão que tem um polímero de carboxivinila tal como um carbômero, uma galactomanana tal como guar, e um composto de borato. um composto de particulado pouco sóluvel tal como nepafenaco também é incluído nas composições. o composto particulado pouco solúvel tem um tamanho de partícula pequeno para realçar biodisponibilidade do composto.
BR112012013503A 2009-12-03 2010-12-01 composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade BR112012013503B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26636809P 2009-12-03 2009-12-03
US61/266,368 2009-12-03
PCT/US2010/058563 WO2011068872A2 (en) 2009-12-03 2010-12-01 Carboxyvinyl polymer-containing nanoparticle suspension

Publications (3)

Publication Number Publication Date
BR112012013503A2 true BR112012013503A2 (pt) 2016-06-07
BR112012013503B1 BR112012013503B1 (pt) 2021-04-20
BR112012013503B8 BR112012013503B8 (pt) 2021-05-25

Family

ID=43425837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013503A BR112012013503B8 (pt) 2009-12-03 2010-12-01 composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade

Country Status (27)

Country Link
US (3) US8921337B2 (pt)
EP (3) EP2506831B1 (pt)
JP (3) JP5864433B2 (pt)
KR (2) KR101543613B1 (pt)
CN (1) CN102724965B (pt)
AR (2) AR080572A1 (pt)
AU (1) AU2010326099B2 (pt)
BR (1) BR112012013503B8 (pt)
CA (1) CA2781254C (pt)
CL (1) CL2012001402A1 (pt)
CY (1) CY1120585T1 (pt)
DK (3) DK2586426T3 (pt)
ES (3) ES2441420T3 (pt)
HK (3) HK1178802A1 (pt)
HR (2) HRP20140016T1 (pt)
HU (2) HUE038821T2 (pt)
LT (1) LT2965749T (pt)
MX (1) MX2012006231A (pt)
PL (3) PL2965749T3 (pt)
PT (3) PT2965749T (pt)
RS (2) RS53085B (pt)
RU (1) RU2571078C2 (pt)
SI (3) SI2965749T1 (pt)
TW (1) TWI486178B (pt)
UY (1) UY33081A (pt)
WO (1) WO2011068872A2 (pt)
ZA (1) ZA201203770B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435631B2 (en) * 2010-04-15 2013-05-07 Ppg Industries Ohio, Inc. Microporous material
DK2596072T3 (da) * 2010-07-20 2014-08-11 C Ip S A Bor-forbindelses-suspension
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
JP2015526515A (ja) * 2012-08-31 2015-09-10 ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ オメガ３脂肪酸を有する眼用組成物
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
US20150191647A1 (en) * 2014-01-07 2015-07-09 Trican Well Service Ltd. Stability of viscous fluids in low salinity environments
EP3721868B1 (en) 2015-01-26 2022-06-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
CN108367026A (zh) * 2015-06-18 2018-08-03 常规制药股份公司 抗微生物配制品
TW201938141A (zh) * 2018-02-21 2019-10-01 瑞士商諾華公司 基於脂質的眼用乳劑
US11730699B2 (en) 2018-02-21 2023-08-22 Alcon Inc. Lipid-based ophthalmic emulsion

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864183A (en) * 1972-11-21 1975-02-04 Tokyo Hat Method for producing pen core from filament tows
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
FR2761959B1 (fr) * 1997-04-15 1999-05-21 Oreal Ensemble de conditionnement et d'application d'un produit fluide
CN1229110C (zh) * 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
DE60237602D1 (de) 2001-06-22 2010-10-21 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
WO2003035080A2 (en) 2001-08-28 2003-05-01 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
BRPI0413381A (pt) 2003-08-07 2006-10-17 Allergan Inc composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TWI393567B (zh) 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
JP4257860B2 (ja) * 2005-04-19 2009-04-22 中得工業株式会社 化粧材の塗布具
PL1885336T3 (pl) * 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
CA2607014A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1893216A4 (en) 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
EP1981491A4 (en) 2006-01-25 2009-09-23 Aciex Inc COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20080181957A1 (en) 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
EP2160182A1 (en) 2007-05-24 2010-03-10 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
TWI526213B (zh) * 2008-04-26 2016-03-21 愛爾康研究有限公司 聚合性人工淚液系統
JP4395189B1 (ja) * 2008-08-29 2010-01-06 株式会社ソリトン 塗布具
AU2010210497B2 (en) * 2009-02-05 2015-07-23 Alcon Research, Ltd. Process for purifying guar
JP5716960B2 (ja) * 2011-05-23 2015-05-13 オーベクス株式会社 塗布体用素材の製造方法及び塗布体用素材並びに塗布体及び塗布具

Also Published As

Publication number Publication date
WO2011068872A8 (en) 2013-04-04
KR20120099269A (ko) 2012-09-07
AR080572A1 (es) 2012-04-18
TW201129395A (en) 2011-09-01
PT2506831E (pt) 2014-01-08
US8921337B2 (en) 2014-12-30
PL2586426T3 (pl) 2016-01-29
AU2010326099B2 (en) 2013-03-07
US9662398B2 (en) 2017-05-30
LT2965749T (lt) 2018-08-10
HRP20181337T1 (hr) 2018-10-19
WO2011068872A3 (en) 2012-01-12
ES2684752T3 (es) 2018-10-04
JP5864433B2 (ja) 2016-02-17
RU2571078C2 (ru) 2015-12-20
HUE025838T2 (en) 2016-04-28
EP2506831B1 (en) 2013-11-20
PT2965749T (pt) 2018-10-09
US20150072011A1 (en) 2015-03-12
EP2965749B1 (en) 2018-05-23
EP2506831A2 (en) 2012-10-10
HUE038821T2 (hu) 2018-11-28
EP2586426A1 (en) 2013-05-01
DK2506831T3 (da) 2013-12-16
HRP20140016T1 (hr) 2014-01-31
DK2586426T3 (en) 2015-11-23
AR122463A2 (es) 2022-09-14
EP2965749A1 (en) 2016-01-13
RS57465B1 (sr) 2018-09-28
HK1170164A1 (en) 2013-02-22
HK1178802A1 (en) 2013-09-19
PT2586426E (pt) 2015-11-17
PL2506831T3 (pl) 2014-05-30
AU2010326099A1 (en) 2012-07-19
US20170020818A1 (en) 2017-01-26
BR112012013503B8 (pt) 2021-05-25
BR112012013503B1 (pt) 2021-04-20
PL2965749T3 (pl) 2018-10-31
ZA201203770B (en) 2013-08-28
CN102724965B (zh) 2015-08-05
KR101809484B1 (ko) 2017-12-15
CA2781254C (en) 2016-06-28
HK1217091A1 (zh) 2016-12-23
SI2506831T1 (sl) 2014-01-31
CY1120585T1 (el) 2019-07-10
JP2015061886A (ja) 2015-04-02
US20110135743A1 (en) 2011-06-09
JP2016106155A (ja) 2016-06-16
SI2586426T1 (sl) 2015-11-30
JP2013512912A (ja) 2013-04-18
SI2965749T1 (sl) 2018-09-28
JP6055849B2 (ja) 2016-12-27
DK2965749T3 (en) 2018-08-27
ES2441420T3 (es) 2014-02-04
CL2012001402A1 (es) 2014-03-28
KR101543613B1 (ko) 2015-08-11
MX2012006231A (es) 2012-07-03
ES2550942T3 (es) 2015-11-13
RU2012127675A (ru) 2014-01-20
CN102724965A (zh) 2012-10-10
EP2586426B1 (en) 2015-09-23
RS53085B (en) 2014-06-30
WO2011068872A2 (en) 2011-06-09
KR20150063587A (ko) 2015-06-09
UY33081A (es) 2011-04-29
CA2781254A1 (en) 2011-06-09
TWI486178B (zh) 2015-06-01

Similar Documents

Publication Publication Date Title
BR112012013503A2 (pt) suspensões de nanopartícula contendo polímero de carboxivinila
BR112013024953A2 (pt) processo para preparar as partículas de pigmento autoligantes, suspensão de partícula de pigmento autoligante, e, uso da suspensão de partícula de pigmento autoligante
TWD161131S (zh) 保溫瓶
TR201909389T4 (tr) Terapötik nanopartikülleri hazırlamaya yönelik proses.
MX2014010323A (es) Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
TWD160228S (zh) 車輛護柵
BR112015001414A2 (pt) composição antideriva
BR112014013792A2 (pt) composição estabilizadora co-atritada, alimento, composição industrial, e, método para fazer a composição estabilizadora
MX2013013979A (es) Uso de marcadores raman para autentificacion de documentos de seguridad.
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
PH12015500887A1 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
IL239327A0 (en) Tetrazole derivatives in solid dispersion, preparations containing them and their uses
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
IN2014DN08412A (pt)
BR112014028066A2 (pt) polietilenoimina etoxilada, polímero de polietilenoimina etoxilada, e, uso de um polímero de polietilenoimina etoxilada
AR093813A1 (es) Composiciones en suspension de finafloxacina
RU2012129335A (ru) Медьсодержащий целлюлозный материал
RU2012124113A (ru) Наноструктурная водно-фосфоритная суспензия в качестве фосфорного удобрения под кукурузу
ES2721270T3 (es) Composiciones de profármaco de aripiprazol
박보미 Living Environment and Policy Issues for the Aged
CY1114871T1 (el) Εναιωρηματα νανοσωματιδιων που περιεχουν πολυμερες καρβοξυβινυλιου
Barry Caught in a Reverie

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF